Citations 1
Phase III trial of [177Lu]Lu-PSMA-617 combined with ADT+ARPI in patients with PSMA-positive metastatic hormone-sensitive prostate cancer (PSMAddition)
Tagawa, S, Sartor, O, Piulats, J M, Saad, F, Fizazi, K, Reid, A H, Beltran, H, Kramer, G, Eiber, M, Gupta, S, Gauna, D E Castellano, Hauke, R, Kim, H, Pang, S-T., Bouillaud, Emmanuel, Zhang, A., Sakharova, O, Morris, M J, Piulats, Josep M. , Saad, Fred , Fizazi, Karim , Reid, A H, Mahammedi, Hakim , Gupta, Shilpa , Gauna, D.E. Castellano, Hauke, Ralph J. , Kwak, Cheol Hun , Zhang, Alison Yan , Sakharova, Olga V., Morris, Michael J.
Nuklearmedizin - NuclearMedicine | April 2, 2026 | Volume: 65 | Issue: 02 | Pages: 107-107
